Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

[1] Huggins C(2002)Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate J Urol. 168 9-12

[2] Hodges CV(2005)Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer. 103 1615-1624

[3] Shahinian VB(1969)Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate Exp Med Surg. 27 406-410

[4] Kuo YF(1981)Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms Cancer. 48 1229-1232

[5] Freeman JL(2013)The utility of prostate-specific antigen in the management of advanced prostate cancer BJU Int. 112 548-560

[6] Orihuela E(2011)Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer J Cancer Res Clin Oncol. 137 235-241

[7] Goodwin JS(2011)Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis Prostate Cancer Prostatic Dis. 14 248-252

[8] Ablin RJ(2011)Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy Prostate. 71 1189-1197

[9] Pfeiffer L(2012)Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy Aging Male. 15 34-41

[10] Gonder MJ(2009)Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy Cancer. 115 981-987

[1] Huggins C(2002)Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate J Urol. 168 9-12

[2] Hodges CV(2005)Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer. 103 1615-1624

[3] Shahinian VB(1969)Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate Exp Med Surg. 27 406-410

[4] Kuo YF(1981)Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms Cancer. 48 1229-1232

[5] Freeman JL(2013)The utility of prostate-specific antigen in the management of advanced prostate cancer BJU Int. 112 548-560

[6] Orihuela E(2011)Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer J Cancer Res Clin Oncol. 137 235-241

[7] Goodwin JS(2011)Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis Prostate Cancer Prostatic Dis. 14 248-252

[8] Ablin RJ(2011)Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy Prostate. 71 1189-1197

[9] Pfeiffer L(2012)Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy Aging Male. 15 34-41

[10] Gonder MJ(2009)Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy Cancer. 115 981-987